| Molecular formula | C76H104N18O19S2 |
|---|
| Molecular weight | 1637.9 g/mol |
|---|
| Registered trials | 567 |
|---|
| PubChem CID | 16129706 |
|---|
What somatostatin is
Somatostatin is a peptide compound identified in chemical databases under PubChem CID 16129706, with a molecular formula of C76H104N18O19S2. It does not have an FDA-approved drug label. This means there is no approved indication, dosing information, or officially reviewed safety profile associated with somatostatin itself, though related somatostatin receptor-targeted agents appear in registered clinical research.
Trial footprint
There are 567 registered clinical trials referencing somatostatin or its receptor pathway. Sampled studies illustrate the range of this research, including a trial evaluating Lu-DOTATATE treatment in patients with somatostatin receptor positive neuroendocrine tumors, currently active but not recruiting. Another sampled study examines Lu-177-DOTATATE in combination with olaparib for inoperable gastroenteropancreatic neuroendocrine tumors and is recruiting participants. A third sampled trial, testing 68Ga-DOTATATE imaging for coronary atherosclerosis detection, has been terminated. These examples reflect registered study activity only and do not indicate that somatostatin itself is an approved or effective treatment for any condition.
FAQ
No. Somatostatin does not carry an FDA-approved label. It remains classified as an unapproved research compound, though related receptor-targeted agents are studied in registered clinical trials.
Registered trials most often study somatostatin receptor pathways in the context of neuroendocrine tumor imaging and treatment, sometimes combined with other investigational agents. These are research applications and do not reflect an approved medical use for somatostatin itself.
There are 567 registered clinical trials referencing somatostatin or its receptor pathway. These span a range of statuses, including active, recruiting, and terminated studies.
Somatostatin is a peptide with the molecular formula C76H104N18O19S2 and a molecular weight of approximately 1637.9. It is catalogued in PubChem under CID 16129706.
No adverse event report data was available for somatostatin in the reviewed dataset. This does not mean side effects do not exist, only that no summarized reporting data was available here.
This page is an editorial information resource. It does not sell, prescribe, or recommend any medication.
Content is editorial information, not medical advice. Talk to your doctor before any treatment decision.
Sources: PubChem ClinicalTrials.gov
Updated 2026-09-19